The number of available model systems for laboratory study of CF continues to expand at a rapid pace. Current options range from genetically modified cell lines or animals to primary human cell models, each offering unique benefits. Many of these models have contributed to the development of current and emerging therapies for patients with CF. Moreover, the use of novel models at the interface of research and clinical care is expanding access to these medications. This symposium will focus on the use of CF-relevant model systems across the therapeutic pipeline from drug screening and development to personalized clinical approaches. Particular emphasis will be placed on the benefits and limitations of each discussed model, and how the choice of each model matches and empowers the study of the therapy in question.
Demonstrate the wide range of complimentary CF-relevant model systems currently in use to study therapeutics.
Discuss the benefits and limitations of CF-relevant cell line, animal, and primary cell-based model systems relative to specific treatments or drugs.
Describe the utility of each unique model system at different stages of the drug development pipeline from discovery to the clinic.
Note: Speaker Christine Bear's presentation was not recorded at her request.